Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD (Daytsleep)
Open Label Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children 6-12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Once the optimal dose of Daytrana that controlled the ADHD symptoms is established. The patch will be removed 1, 2, and 3 hours before bed time in a random fashion, at weekly intervals, and parents will keep a sleep diary.
25 patients will be enrolled in order to obtain statistical significance.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
Springfield, Missouri, United States, 65807
- Pediatric Neurology of the Ozarks
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ADHD without significant comorbidity
Exclusion Criteria:
- Cardiac disorder
- Hypertension
- Thyroid disease
- Glaucoma
- History of sudden death, motor tics and/or Tourette's syndrome
- Hypersensitivity to methylphenidate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Daytrana 9 hr wear
|
Daytrana patch 10-30 mg administered once daily for 9hr
Other Names:
Daytrana 10-30 mg worn once daily for 10 hr wear
Other Names:
Daytrana 10-30 mg worn once daily for 11 hr
Other Names:
Daytrana 10-30 mg worn once daily for 12 hrs
|
|
Experimental: Daytrana 10 hr wear
|
Daytrana patch 10-30 mg administered once daily for 9hr
Other Names:
Daytrana 10-30 mg worn once daily for 10 hr wear
Other Names:
Daytrana 10-30 mg worn once daily for 11 hr
Other Names:
Daytrana 10-30 mg worn once daily for 12 hrs
|
|
Experimental: Daytrana 11 hr wear
|
Daytrana patch 10-30 mg administered once daily for 9hr
Other Names:
Daytrana 10-30 mg worn once daily for 10 hr wear
Other Names:
Daytrana 10-30 mg worn once daily for 11 hr
Other Names:
Daytrana 10-30 mg worn once daily for 12 hrs
|
|
Experimental: Daytrana 12 hr wear
|
Daytrana patch 10-30 mg administered once daily for 9hr
Other Names:
Daytrana 10-30 mg worn once daily for 10 hr wear
Other Names:
Daytrana 10-30 mg worn once daily for 11 hr
Other Names:
Daytrana 10-30 mg worn once daily for 12 hrs
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sleep Latency
Time Frame: 9 weeks
|
Measure by daily subject sleep diary
|
9 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: arie ashkenasi, Pediatric Neurology of the Ozarks
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Methylphenidate
Other Study ID Numbers
Other Study ID Numbers
- cox002
- shire IND#54,732 (Other Identifier: Shire Pharmaceuticals)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.